Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease

Alicia Lacoma, Cristina Prat, Felipe Andreo, Luis Lores, Juan Ruiz-Manzano, Vicente Ausina, Jose Domínguez

Research output: Contribution to journalArticleResearchpeer-review

49 Citations (Scopus)

Abstract

Objective: The identification of biological markers in order to assess different aspects of COPD is an area of growing interest. The objective of this study was to investigate whether levels of procalcitonin (PCT), C-reactive protein (CRP), and neopterin in COPD patients could be useful in identifying the etiological origin of the exacerbation and assessing its prognosis. Methods: We included 318 consecutive COPD patients: 46 in a stable phase, 217 undergoing an exacerbation, and 55 with pneumonia. A serum sample was collected from each patient at the time of being included in the study. A second sample was also collected 1 month later from 23 patients in the exacerbation group. We compared the characteristics, biomarker levels, microbiological findings, and prognosis in each patient group. PCT and CRP were measured using an immunofluorescence assay. Neopterin levels were measured using a competitive immunoassay. Results: PCT and CRP showed significant differences among the three patient groups, being higher in patients with pneumonia, followed by patients with exacerbation (P < 0.0001). For the 23 patients with paired samples, PCT and CRP levels decreased 1 month after the exacerbation episode, while neopterin increased. Neopterin showed significantly lower levels in exacerbations with isolation of pathogenic bacteria, but no differences were found for PCT and CRP. No significant differences were found when comparing biomarker levels according to the Gram result: PCT (P = 0.191), CRP (P = 0.080), and neopterin (P = 0.109). However, median values of PCT and CRP were high for Streptococcus pneumoniae, Staphylococcus aureus, and enterobacteria. All biomarkers were higher in patients who died within 1 month after the sample collection than in patients who died later on. Conclusions: According to our results, biomarker levels vary depending on the clinical status. However, the identification of the etiology of infectious exacerbation by means of circulating biomarkers is encouraging, but its main disadvantage is the absence of a microbiological gold standard, to definitively demonstrate their value. High biomarker levels during an exacerbation episode correlate with the short-term prognosis, and therefore their measurement can be useful for COPD management. © 2011 Lacoma et al, publisher and licensee Dove Medical Press Ltd.
Original languageEnglish
Pages (from-to)157-169
JournalInternational Journal of COPD
Volume6
Issue number1
DOIs
Publication statusPublished - 1 Dec 2011

Keywords

  • C-reactive protein
  • Exacerbation
  • Neopterin
  • Procalcitonin
  • Prognosis

Fingerprint Dive into the research topics of 'Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this